Zim Laboratories Ltd (ZIMLAB) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Zim Laboratories Ltd on NSE and BSE, with an AI summary of each filing.
We wish to inform you that Q2 & H1FY27 Earnings Conference Call is scheduled to be held on Thursday, 05th November, 2026 at 11:00 a.m. IST.
Intimation · 31 Oct 2026, 7:44 pm
ZIM Laboratories Schedules Q2 and H1FY27 Earnings Conference Call ZIM Laboratories Limited has scheduled its Q2 & H1FY27 earnings conference call for Thursday, 5th Nov'26 at 11:00 AM IST. Hosted by Go India Advisors, the management team—including Chairman and Managing Director Dr. Anwar Siraj Daud, Director (Finance) Zulfiquar Kamal, Chief Financial Officer Shyam Mohan Patro, and Investor Relations representative Zain Daud—will discuss the operational and financial performance. Universal dial-in access numbers for the call include +91 22 6280 1557 and +91 22 7115 8383.
ZIM Laboratories Limited has informed the Exchange about Board Meeting to be held on 04-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 .
Intimation · 04 Nov 2026, 5:30 am
Zim Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/11/2026 ,inter alia, to consider and approve the Unaudited Financial Results ....
Intimation · 04 Nov 2026, 5:30 am
ZIM Laboratories Board Meeting Scheduled for 4th Nov'26 to Consider Q2 Results ZIM Laboratories Limited has scheduled a meeting of its Board of Directors on 4th Nov'26 to consider and approve the standalone and consolidated unaudited financial results for the quarter ended 30th Sep'26. In accordance with SEBI insider trading regulations, the trading window for dealing in company securities remains closed from 1st Oct'26 through 6th Nov'26 (both days inclusive).
To consider and approve the financial results for the period ended September 30, 2026
Intimation · 04 Nov 2026, 5:30 am
Please find enclosed the Press Release relating to grant of GMP Certification of Compliance by Australia''s TGA to the Company for its manufacturing facility.
Press Release · 16 Oct 2026, 6:24 pm
ZIM Laboratories Receives Australia TGA GMP Certification for Nagpur Facility ZIM Laboratories received a Good Manufacturing Practice (GMP) Certificate of Compliance from Australia’s Therapeutic Goods Administration (TGA) on 15th Oct'26 for its Kalmeshwar, Nagpur manufacturing facility. Following an inspection in Apr'26, the approval covers non-sterile finished products including tablets, capsules, granules, wafers, and soluble films across registered and listed categories. Valid until 21st Jun'28 with no operational conditions attached, the certification enables ZIM to pursue commercial partnerships in Australia and bolsters its regulatory credentials across Rest of World (RoW) markets.
Please find enclosed the disclosure under Regulation 30 of SEBI (LODR) Regulations 2015 regarding Credit Rating
Others (Uncategorized) · 09 Oct 2026, 1:50 am
CARE Ratings Reaffirms ZIM Laboratories’ Ratings, Revises Long-Term Outlook to Negative CARE Ratings reaffirmed ZIM Laboratories Limited’s credit ratings across its bank facilities while revising the outlook on long-term facilities to 'Negative' from 'Stable'. The company's long-term bank facilities totaling Rs 127.48 crore were reaffirmed at 'CARE BBB/Negative'. Additionally, short-term bank facilities amounting to Rs 12.00 crore were reaffirmed at 'CARE A3'. Total rated bank facilities stand at Rs 139.48 crore.
Intimation for incorporation of wholly owned subsidiary
Others (Uncategorized) · 18 Sept 2026, 1:41 pm
ZIM Laboratories Incorporates Wholly Owned Subsidiary in Chile ZIM Laboratories Limited has incorporated a 100% wholly owned subsidiary, ZIM Laboratories SpA, in Santiago, Chile, on 9th Sep'26. The holding company subscribed to 14,100 shares at a face value of CLP 1,000 each via cash consideration. The move aims to drive the expansion and development of the company's pharmaceutical business across the LATAM region.
Update on completion of investment in the share capitalof ZIM Scientific Office L.L.C. (Step Down Subsidiary) by ZIM Laboratories Limited FZE, wholly owned subsidiary
Others (Uncategorized) · 16 Sept 2026, 1:21 am
ZIM Laboratories Completes Full Subsidiary Capital Infusion in ZIM Scientific Office ZIM Laboratories Limited announced that its wholly owned subsidiary, ZIM Laboratories Limited FZE, has completed the full approved equity investment in step-down subsidiary ZIM Scientific Office LLC. Following prior disclosures on 28th Mar'25 and 7th Aug'25 regarding planned investments of AED 4,66,000 and AED 4,50,000, respectively, the entire approved amount has now been infused into ZIM SO's share capital. Post-investment, ZIM FZE continues to retain a 100% shareholding in ZIM SO.
Transcript of Q1 FY27 Earning Conference call
Transcript · 13 Aug 2026, 12:50 am
Please find enclosed the disclosure for the Link of Audio recording of Earnings Call Q1FY27.
Audio / Video · 08 Aug 2026, 4:01 pm
ZIM Laboratories Discloses Q1 FY27 Earnings Call Audio Recording ZIM Laboratories (ZIMLAB) has disclosed the audio recording of its Q1 FY27 earnings conference call, held on 08 Aug'26. The disclosure was made to the BSE and NSE in compliance with SEBI's Listing Obligations and Disclosure Requirements Regulations, 2015. The recording is accessible via a link provided in the official filing. This allows investors and analysts to access management's discussion and outlook following the release of the company's quarterly financial results.
Please find enclosed the Unaudited Financial Results for the Quarter ended 30th June 2026.
Financial Result · 06 Aug 2026, 9:25 pm
ZIM Laboratories Reports Q1FY27 Net Loss; Revenue Rises YoY ZIM Laboratories reported a consolidated net loss of ₹401.70 lakhs for Q1FY27, a significant shift from a net profit of ₹373.99 lakhs in Q4FY26 and a net loss of ₹187.49 lakhs in Q1FY26. Revenue from operations grew 31.2% YoY to ₹9,417.85 lakhs but declined 10.5% QoQ. Total expenses increased 33.1% YoY to ₹10,074.38 lakhs. The company’s loss before tax stood at ₹557.30 lakhs for the quarter ended 30th Jun'26. Basic EPS was negative at (₹0.75) versus (₹0.38) in the prior-year quarter.
Please find enclosed the Financial Results for the Quarter ended 30th June 2026.
Outcome · 06 Aug 2026, 7:28 pm
Zim Laboratories Ltd - Financial Result for the Quarter ended 30th Jun'26 (Consolidated, INR Lakh) ■ Revenue: 9,418 (+31.2% YoY | -10.5% QoQ) ■ EBITDA: 245 (-42.5% YoY | -65.9% QoQ) ■ EBITDA Margin (%): 2.6 (-333 bps YoY | -423 bps QoQ) ■ PAT: -402 (-114.2% YoY | Profit to Loss QoQ) ■ EPS (INR): -0.75 (-97.4% YoY | Profit to Loss QoQ)
Please find attached disclosure under Regulation 30 read with Scheduled III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for Earnings Conference Call for ....
Intimation · 07 Aug 2026, 12:00 pm
ZIM Laboratories Schedules Q1FY27 Earnings Conference Call for 07 Aug'26 ZIM Laboratories (ZIMLAB) has scheduled its Q1FY27 earnings conference call for Friday, 07 Aug'26, at 12:00 PM IST. The call, hosted by Go India Advisors, will feature key management including Director (Finance) Mr. Zulfiquar Kamal and CFO Mr. Shyam Mohan Patro. This event will provide an opportunity for investors and analysts to discuss the company's financial and operational performance for the quarter ending Jun'26. The company filed this intimation with the BSE and NSE exchanges on 04 Aug'26.
Zim Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/08/2026 ,inter alia, to consider and approve Unaudited Financial Results ....
Intimation · 06 Aug 2026, 5:30 am
Zim Laboratories Board Meeting Set to Approve Q1FY27 Financial Results Zim Laboratories will hold a Board of Directors meeting on 06th Aug'26 to consider and approve the unaudited standalone and consolidated financial results for the quarter ended 30th Jun'26. In connection with this, the trading window for dealing in the company's securities is closed for insiders from 01st Jul'26 to 08th Aug'26, inclusive.
Please find enclosed the disclosure regarding allotment of equity shares of the Company pursuant to exercise of stock options by the eligible employees under ZIM Laboratories Employee Stock ....
Others (Uncategorized) · 13 Jul 2026, 6:01 pm
ZIM Laboratories Allots Equity Shares Under ESOS 2023 On 13th Jul'26, ZIM Laboratories allotted 1,09,451 equity shares of Rs. 10 face value to employees under its ESOS 2023. The shares were exercised at a price of Rs. 77.40 per share. Following this allotment, the company's paid-up equity share capital increased from Rs. 53.54 crore to Rs. 53.65 crore. The total number of issued shares now stands at 5,36,58,488. The newly allotted shares will rank pari-passu with existing equity shares.
Disclosure under Regulation 30 of SEBI (LODR) 2015, with respect to schedule of Investor/ Analyst Meeting
Intimation · 01 Jul 2026, 4:06 am
ZIM Laboratories Schedules Investor Meeting with Canara HSBC Life Insurance ZIM Laboratories (ZIMLAB) has scheduled a one-to-one, in-person meeting with Canara HSBC Life Insurance on 03rd Jul'26. The meeting was disclosed under SEBI's LODR Regulations, 2015. The company stated that no Unpublished Price Sensitive Information (UPSI) will be shared during the discussion. The schedule is subject to change based on exigencies.
Disclosure under Regulation 30 of SEBI (LODR) 2015, with respect to schedule of Investor/ Analyst Meeting
Intimation · 30 Jun 2026, 9:05 pm
ZIM Laboratories Schedules Investor Meeting with Tata Asset Management ZIM Laboratories (ZIMLAB) has scheduled a one-to-one investor meeting with Tata Asset Management Pvt. Ltd. The meeting will take place on 03rd Jul'26 and will be conducted in person. The company confirmed that no Unpublished Price Sensitive Information (UPSI) will be shared during the engagement. The schedule is subject to change based on any unforeseen exigencies.
Disclosure under Regulation 30 of SEBI (LODR) 2015, with respect to schedule of Investor/ Analyst Meeting
Intimation · 30 Jun 2026, 9:04 pm
ZIM Laboratories Schedules One-to-One Investor Meeting with Tata Asset Management ZIM Laboratories Limited has scheduled a one-to-one, in-person meeting with Tata Asset Management Pvt. Ltd on 03rd Jul'26. This interaction is disclosed under Regulation 30 of the SEBI (LODR) Regulations, 2015. The company confirmed that no Unpublished Price Sensitive Information (UPSI) will be shared during the meeting. The schedule is subject to change based on any exigencies.
Please find enclosed the Voting Results under Regulation 44 of SEBI (LODR) Regulations 2015 along with the Scrutinizers Report of the 42nd Annual General Meeting of the Company held on 29th June 2026
Annual General Meeting · 30 Jun 2026, 1:15 am
Please find enclosed the Proceedings of the 42nd Annual General Meeting held on 29th June 2026 along with the Scrutinizers Report.
Annual General Meeting · 30 Jun 2026, 1:10 am
The Exchange has received the disclosure under Regulation 10(6) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Dr Anwar Daud
Others (Uncategorized) · 16 Jun 2026, 10:56 pm
ZIMLAB: Promoter Anwar Daud Acquires 0.15% Stake in Inter-se Transfer ZIM Laboratories promoter Dr. Anwar Daud acquired 80,000 equity shares, representing a 0.15% stake, from fellow promoter Mr. Zulfiquar Kamal on 11 Jun'26. The transaction, an inter-se transfer, was executed at a price of INR 107.50 per share. Post-acquisition, Dr. Anwar Daud's shareholding increased from 24.90% to 25.05%, while Mr. Zulfiquar Kamal's stake decreased from 2.23% to 2.08%. The acquisition qualifies for exemption under SEBI SAST regulations. This filing was made to exchanges on 15 Jun'26.
Disclosure under Regulation 30 of SEBI (LODR) 2015, with respect to schedule of Investor/ Analyst Meeting
Intimation · 15 Jun 2026, 10:28 pm
ZIM Laboratories Schedules Investor Meeting with Florintree Trinex LLP ZIM Laboratories (ZIMLAB) has scheduled a one-to-one, in-person meeting with investor/analyst Florintree Trinex LLP on 19 Jun'26. The meeting was disclosed in compliance with SEBI LODR regulations. The company noted that the schedule is subject to change due to exigencies and confirmed that no Unpublished Price Sensitive Information (UPSI) will be shared during the discussion.
Please find enclosed the schedule of investor meet to be held on 17th June 2026 at 4:00 pm
Intimation · 13 Jun 2026, 8:59 pm
ZIM Laboratories to Hold Virtual Investor Meeting with Long Equity ZIM Laboratories (NSE: ZIMLAB) has scheduled a virtual one-to-one investor/analyst meeting with Long Equity on 17th Jun'26. This engagement follows the company's disclosure under Regulation 30 of SEBI LODR. The company stated that no Unpublished Price Sensitive Information (UPSI) will be shared during the meeting. The schedule is subject to change based on any exigencies.
Pursuant to Regulation 36(1)(b) of SEBI(LODR) Regulations 2015 please find enclosed the letter sent to members providing weblink of Annual Report for F.Y. 2025-26
Annual Report · 06 Jun 2026, 12:32 am
Please find enclosed the Annual Report for the F.Y. 2025-26.
Others (Uncategorized) · 05 Jun 2026, 11:33 pm
ZIM Labs FY26: Margins Compressed Amid EU-GMP Remediation, Stable Topline ZIM Laboratories reported flat Total Operating Income of ₹3,744 Mn for FY26, impacted by geopolitical issues and a temporary pause in EU-GMP accreditation. EBITDA declined 16.4% YoY to ₹414 Mn, with PAT margin compressing by 160 bps to 1.6%. Export revenue grew a marginal 0.8% YoY to ₹3,150 Mn, while domestic revenue fell. The innovative products (NIP+OTF) portfolio contributed 15% to revenue. Key priorities include regaining EU-GMP accreditation in FY27 to unlock European market access for its innovative product pipeline.